<DOC>
	<DOCNO>NCT00005837</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness oxaliplatin treat patient recurrent refractory cervical cancer .</brief_summary>
	<brief_title>Oxaliplatin Treating Patients With Recurrent Refractory Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity oxaliplatin measure response rate patient recurrent refractory squamous cell carcinoma cervix fail high priority treatment protocol . II . Determine nature degree toxicity drug patient population . OUTLINE : Patients receive oxaliplatin IV 2 hour . Treatment continue every 21 day maximum 9 course absence unacceptable toxicity disease progression . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 22-60 patient accrue study within 12-14 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm refractory recurrent squamous cell carcinoma cervix fail local therapeutic measure consider incurable Bidimensionally measurable disease Must eligible high priority GOG protocol No known brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Granulocyte count least 1,500/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 3 time ULN Alkaline phosphatase great 3 time ULN Renal : Creatinine normal Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : Not pregnant nursing Fertile patient must use effective contraception No evidence preexist peripheral sensory neuropathy great CTC grade 1 , include residual neuropathy attribute prior chemotherapy chronic condition ( e.g. , diabetes , venous stasis , carpal tunnel syndrome ) No history allergy platinum compound antiemetic appropriate administration conjunction protocol direct chemotherapy No uncontrolled concurrent illness ( e.g. , ongoing active infection ) No malignancy within past 5 year except nonmelanoma skin cancer prior malignancy whose prior cancer treatment contraindicate protocol therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent colony stimulate factor ( CSFs ) first course therapy At least 24 hour since prior CSFs subsequent course therapy Chemotherapy : At least 3 week since prior chemotherapy recover No prior oxaliplatin No 1 prior chemotherapy regimen Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : At least 3 week since prior surgery recover Other : At least 3 week since prior anticancer therapy recover No concurrent investigational agent No concurrent antiretroviral therapy ( HAART )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>